Why is alkaline phosphatase (ALP) elevated in bone disease, and how does ALP isoenzyme testing help?

• A. ALP is most abundant in liver; isoenzyme testing confirms hepatic source.
• B. ALP is abundant in bone; increased bone turnover raises ALP; isoenzyme testing distinguishes hepatic from bone sources.
• C. ALP elevations are not related to bone activity.
• D. Isoenzyme testing cannot distinguish sources.

Answer: (B)

Bone turnover and osteoblastic activity drive the production of the bone-specific alkaline phosphatase (ALP). When bone disease or repair accelerates, osteoblasts release more ALP to aid mineralization, so the total ALP in blood rises. ALP comes from multiple tissues, notably bone and liver, so an elevated ALP could reflect either bone remodeling or hepatic/cholestatic processes.

Isoenzyme testing lets us separate the ALP coming from bone from that coming from the liver. By methods such as electrophoresis or using specific antibodies or inhibitors, the different tissue forms are distinguished, revealing whether the predominant activity is bone-derived. This is why elevated ALP in bone disease is best confirmed with isoenzyme testing—it shows the source is bone rather than liver, guiding accurate interpretation and management.

The other ideas aren’t correct because ALP is not only abundant in the liver, and elevations can indeed reflect bone activity. Isoenzyme testing can distinguish the sources, and recognizing bone-origin ALP helps differentiate between metabolic bone disease and hepatic causes.